Table 1.
Baseline summary of the patient population
| Characteristic | Value* | Missing data (%) | |
|---|---|---|---|
| DAS28 | 5.6 (1.8–8.5) | 0 | |
| Follow-up | 52 (0–60) | 0 | |
| Age (years) | 57 (18–86) | 0 | |
| Weight (kg) | 72.5 (40.4–143.5) | 22 | |
| BMI (kg m−2) | 27.4 (16.1–60.5) | 22 | |
| Gender | Female | 187 (71%) | 0 |
| Smoking status | Never | 123 (47%) | 5 |
| Current | 48 (18%) | ||
| Past | 79 (30%) | ||
| Corticosteroid† | Administration | 125 (48%) | 0 |
| anti-CCP | Positive | 143 (55%) | 2 |
| Rheumatoid factor | Positive | 155 (59%) | 0 |
| Shared epitope | Positive | 159 (64%) | 6 |
*
Continuous variables are represented as median (minimum–maximum) and categorical variables are represented as the proportion of individuals with that characteristic when excluding missing data. BMI = body mass index; anti-CCP = anti-cyclic-citrullinated-peptide antibodies at diagnosis.
†
‘Corticosteroid administration’ consists of those individuals who received any dose of i.a., i.m. or oral corticosteroids throughout the 60 week period. Doses administered were converted to oral prednisolone equivalent doses with a mean of 0.93 mg day−1.